| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 34.36 | 0.19 (+0.56%) | 17.96 - 42.67 | 20.8 thousand (Below Avg) |
Market data as of 4:00PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 34.33 |
|---|---|
| Previous Close | 34.17 |
| Day's Range | 34.24 - 34.51 |
| Market Cap | 577.4M |
| Avg Volume (10 Day) | 42.0K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -5.2 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Intercept Pharmaceuticals to Present at Deutsche Bank Healthcare Conference
PR Newswire - Thursday 05/23/2013 8:03 AM ET
Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea
PR Newswire - Monday 05/20/2013 8:00 AM ET
| ICPT | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 432.85 |
| Company | Last | Change |
|---|---|---|
| Astex Pharmaceuticals Inc | 5.36 | +4.69% |
| Endocyte Inc | 14.02 | 0.00% |
| Keryx Biopharmaceuticals Inc | 8.03 | 0.00% |
| Rigel Pharmaceuticals Inc | 4.71 | +1.51% |
| KYTHERA Biopharmaceuticals Inc | 20.81 | 0.00% |
Data is delayed by at least 15 min.